Adalvo has achieved another milestone by successfully completing its Pivotal BE program for the 0.15mg/0.02mg strength of its Desogestrel+Ethinylestradiol film-coated tablets, following the recent news of the completion of the BE Study for the higher strength.
This accomplishment enables Adalvo to provide multiple treatment options to both partners and patients.
Our Desogestrel+Ethinylestradiol 0.15mg/0.02mg film-coated tablets were developed in collaboration with one of our strategic partners, based on the reference brand Mercilon film-coated tablets. The product is a low-dose contraceptive used by women to prevent pregnancy.
According to IQVIA, the INN with strength 0.15mg/0.02mg generated approximately $93mn in global sales in 2021.
As a company committed to women's health, we offer an array of dossiers and aim to assist our partners in overcoming any challenges that may arise with these mature products.
